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Aim To determine the association between the number 
of thymine-adenine (TA)n dinucleotide repeats in the pro-
moter region of the gene coding for the estrogen receptor 
alpha (ESR1) and the prevalence of lone atrial fibrillation 
(AF) in men.
Methods We conducted a case-control study involving 89 
men with lone AF and 166 healthy male controls. The ESR1 
genotype was established by polymerase chain reaction 
and capillary electrophoresis. To assess the association of 
ESR1 genotype with AF, logistic regression models were 
built with AF as outcome.
Results Men with lone AF had significantly greater 
number of (TA)n repeats of single alleles than controls 
(mean ± standard deviation, 19.2 ± 4.2 vs 18 ± 4.3, P = 0.010). 
After adjustment for other factors, a unit-increase in (TA)n 
repeat number was associated with a significantly greater 
likelihood of AF (odds ratio 1.069; 95% confidence interval 
1.024-1.116, P = 0.002).
Conclusions Our results indicate that a greater number of 
(TA)n repeats in the promoter region of ESR1 is associated 
with a significantly increased likelihood of lone atrial fibril-
lation in men.
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Atrial fibrillation (AF) is considered the most common sus-
tained arrhythmia of clinical importance (1). Even if cor-
rected for etiological factors such as ischemic and hyper-
tensive heart disease, its prevalence in men is 1.5 times 
higher than in women (1). lone AF is defined as a normal 
echocardiogram and no clinical history of known etiologi-
cal factors for AF and it occurs in the normal heart without 
any known causal factor (2). It has similar sex prevalence as 
AF, and such prevalence may indicate the effects of sexual 
hormones on cardiac electrophysiology through the cor-
responding intracellular steroid receptors (3).
Genetic determinants of AF have been explored using 
different methods, ranging from candidate gene studies 
investigating rare mutations (4) with alterations in cardi-
omyocite structure and function (mostly ion channel al-
terations) to genome-wide association studies examining 
subtle effects of single nucleotide polymorphisms (5). Nu-
cleotide polymorphisms have been widely investigated, 
mostly those affecting ion channel function, cardiac renin-
angiotensin-aldosterone system, inflammatory responses, 
and cardiac connexins (6-12)
Less attention, however, has been paid to the association 
of AF and nucleotide polymorphisms of cardiac sexual 
steroid receptors. Sexual steroid hormones exert complex 
genomic and non-genomic cardiac effects through corre-
sponding receptors (13). The gene coding for the estrogen 
receptor α (ESR1) is located on chromosome 6 (6q25–27). 
It comprises eight exons and has a polymorphic thymine-
adenine (TA) region located 1174 base pairs (bp) upstream 
from the exon 1 in the genes promoter region. Out of many 
ESR1 polymorphisms, alleles with a larger number of (TA)n 
repeats have received the most research attention, making 
it one of the most promising research targets (14). A pre-
vious study suggested a positive correlation between ho-
mozygosity for longer alleles (≥19 TA repeats) and AF (15). 
Therefore, we aimed to examine the association between 
the actual number of (TA)n repeats and lone AF in men us-
ing a case-control design.
MAteriALS And MethodS
Study population
This case-control study included 89 male patients with 
lone AF and otherwise structurally and functionally nor-
mal hearts and 166 healthy male participants without any 
known disease. All participants were of Caucasian origin re-
cruited from the city of Zagreb and the wider region and 
were included in the study as they appeared in our hospital 
or outpatient clinic from January 2010 to December 2012 
(Figure 1). Informed consent was obtained from each per-
son and the study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki. The study was ap-
proved by the Medical Ethics Committee of the hospital.
Cases
The main inclusion criterion for the AF group was electro-
cardiographically (ECG) documented AF in the absence of 
known etiological factors for AF (ie, hypertension, sympto-
matic heart failure, valvular heart diseases, cardiomyopa-
thies, congenital heart defects, coronary artery disease, 
thyroid dysfunction, obesity, diabetes mellitus, chronic 
obstructive pulmonary disease, sleep apnea, and chronic 
renal disease) (16). All AF patients underwent a non-inva-
sive cardiologic evaluation, including echocardiography. 
Patients with a history of smoking, drug use, and alcohol 
intake were excluded (Figure 1).
Controls
The control group consisted of volunteers from the pre-
ventive health check program with healthy hearts and 
normal electrocardiograms. On physical examination they 
were found to have no signs or symptoms of any disease, 
as people with not normal test results were excluded from 
the study (Figure 1) (Supplementary Table). The necessary 
sample size was calculated beforehand using expected fre-
quencies from our previous research, 2:1 control to case 
ratio, type I error probability of 0.05, and statistical pow-
er of 80% by standard methods assuming that outcome 
data will be analyzed prospectively by uncorrected χ2 test. 
The calculations yielded 65 cases and 130 controls. Sample 
size calculation for logistic regression was obtained by the 
Peduzzi method for 4 covariates and prevalence of 35%. 
The minimum required total sample size (cases + controls) 
was 114. Our sample of 255 was thus large enough for ad-
equate analysis.
Methods
Height was measured using a Harpender stadiometer and 
weight on a digital scale without shoes. Body mass index 
(BMI) was calculated as the weight in kilograms divided 
by the square of height in meters. Blood pressure was 
measured in a sitting position using a standard analog 
sphygmomanometer. Mean arterial pressure (MAP) 
was calculated by the formula: systolic blood pres-
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sure (SBP) × 1/3 + diastolic blood pressure (DBP) × 2/3. The 
serum estradiol level was assessed by a competitive immu-
noassay technique (Ortho Johnson & Johnson, High Wy-
combe, UK).
echocardiographic data
The transthoracic echocardiogram was performed using 
a GE Vivid 7 echocardiograph (GE Healthcare, Little Chal-
font, UK). All examinations were performed by cardiolo-
gists with accreditation in transthoracic echo-cardiogra-
phy by the European Society of Cardiology. The images 
were later reanalyzed using the GE Health Care EchoPac 
Dimension software, PC version 108.1.3 (GE Healthcare, 
Little Chalfont, UK).
Assessment of eSr1 genotype
Genomic DNA was extracted from peripheral blood leu-
cocytes using the Nucleon II DNA extraction kit (Scotlab, 
FiGure 1. the stepwise exclusion process of cases and controls.
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Coatbridge, Lanarkshire, UK) according to the manufactur-
er’s instructions. Analysis was performed within one week 
after the blood sample was obtained.
Dinucleotide polymorphism of ESR1 was analyzed using 
polymerase chain reaction (PCR) amplification with labeled 
primer 5’-6-FAM-GAC GCA TGA TAT ACT TCA CC-3’ and 5’- 
GCA GAA TCA AAT ATC CAG ATG-3’. PCR was performed 
with 25 cycles consisting of 2 minutes at 94°C, 1 minute at 
58°C, and 1 minute at 72°C, followed by 30 minutes at 60°C 
after the last cycle. The alleles were size-separated by capil-
lary gel electrophoresis using Gene Scan Fragment Analy-
sis Software 4.0 (Applied Biosystems, Foster City, USA). In 
short, 1 µL of the product was diluted with 12 µL of deion-
ized formamide containing 0.5 µL GeneScan-500 ROX in-
ternal lane standard for sizing DNA fragments. Capillary 
electrophoresis was then carried out using ABI PRISM 310 
Genetic Analyzer and POP-6 (Applied Biosystems, Foster 
City, CA, USA), which had been created for applications re-
quiring high resolution under denaturing electrophoretic 
conditions (17).
Statistical analysis
Data are shown as mean values with the standard devia-
tion (SD) for continuous variables and absolute numbers 
with prevalence (%) for categorical variables. Departure 
from normal distribution was initially evaluated for all con-
tinuous variables by Kolmogorov-Smirnov test and graphi-
cally. Mann-Whitney U test and Kruskal-Wallis test were 
conducted to compare the differences between cases and 
controls for continuous variables and χ2 test for categori-
cal variables. To assess the association of ESR genotype 
with AF, binary logistic regression models were built with 
AF as outcome. Model 1 was unadjusted, whereas Model 2 
was adjusted for age, MAP, and serum estradiol concentra-
tion. Likelihood ratio test was used to determine the sig-
nificance of odds ratios. For all analyses, we used statistical 
package STATISTICA, version 9.1. (www.statsoft.com) and a 
double-sided P < 0.05 was considered significant.
reSuLtS
There was no significant difference in clinical, echocardiog-
raphycal, and biochemical characteristics between cases 
and control group (Table 1). We observed 16 different alle-
les with (TA)n repeat number ranging between 11 and 26. 
This polymorphism showed a bimodal distribution, with 
two peaks – at 14 repeats (19.2% of alleles) and 23 repeats 
(12% of alleles), and a breakpoint at 17 and 18 repeats as 
described in earlier studies (18). The same bimodal pattern 
tAbLe 1. Clinical, echocardiographycal, and hormonal characteristics of cases and controls
Atrial fibrillation cases (n = 89) Controls (n = 166) P value*
Age (years)  47.93 ± 11.76  46.34 ± 10.02 0.124
Systolic blood pressure (mmHg) 119.8 ± 7.3 119.4 ± 7.2 0.660
Diastolic blood pressure (mmHg)  77.3 ± 4.8  77.5 ± 4.7 0.803
Body mass index (kg/m2)  23.1 ± 3.1  22.9 ± 2.9 0.629
End-diastolic diameter of the left ventricle (cm)   5.09 ± 0.34    5.05 ± 0.33 0.865
Interventricular septum thickness (cm)   0.94 ± 0.15   0.92 ± 0.16 0.768
Posterior wall (of the left ventricle) thickness (cm)   0.84 ± 0.15   0.85 ± 0.14 0.840
Ejection fraction (of the left ventricle) (%)  66 ± 5.0  66 ± 4.5 0.775
Left atrium transverse axis length (end-systolic) (cm)   3.85 ± 0.66   3.95 ± 0.52 0.757
Left atrium volume (end- systolic) (mL)  41.74 ± 20.1  41.64 ± 19.2 0.816
Right atrium volume (end-systolic) (mL)  30.42 ± 14.71  30.37 ± 13.3 0.854
Estradiol (pmol/L)  54.8 ± 12.2  55.2 ± 11.3 0.726
*Continuous variables were compared using two-tailed Mann-Whitney test.
FiGure 2. bimodal distribution of (tA)n repeats in cases and 
controls.
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emerged when we analyzed the distribution of TA repeats 
by group (Figure 2).
The ESR1 gene promoter TA repeats were classified as short 
(≤18 TA repeats, 160-176 bp) and long (≥19 TA repeats, 178-
194 bp), corresponding to their bimodal distribution and 
in accordance with previous studies on cardiovascular dis-
eases and non-cardiovascular diseases (18). Consequently, 
3 possible genotypes were studied: SS (both alleles short), 
LL (both alleles long), and SL (mixed, one long and one 
short allele). Men with lone AF had a higher prevalence of 
homozygous LL combination than the control group (35 
[39.33%] vs 33 [19.88%], P = 0.003, χ2 = 11.7, χ2 test), while 
the prevalence of the SL combination (36 [40.45%] vs 81 
[48.8%], P = 0.202, χ2 = 1.625, χ2 test) and the SS combina-
tion (18 [20.22%] vs 52 [31.33%], P = 0.058, χ2 = 3.585, χ2 
test) were lower in the AF group.
In order to clarify the relationship between the allele length 
and phenotype, we compared the number of (TA)n repeats 
in single alleles between the AF and control group and 
found a significant difference (19.2 ± 4.2 vs 18 ± 4.3, Mann-
Whitney U test, two-tailed, P = 0.010). We also created (post 
hoc for analysis purposes) five groups of examinees based 
on the sum of (TA)n repeats of both of their alleles to be 
used as predictors and observed greater prevalence of AF 
with a greater sum of (TA)n repeats in a dose-dependent 
manner (χ2 = 14.537, P = 0.006), while serum estradiol con-
centration did not differ significantly between the groups 
(Kruskal-Wallis test: H = 4.93, df = 4, P = 0.295) (Figure 3).
To test whether the observed relationship was confound-
ed by already known risk factors of AF, logistic regression 
was performed (Table 2). In Model 1 (unadjusted), there 
was a 6.9% significantly greater likelihood of AF associated 
with a unit-increase in (TA)n repeat number of single al-
leles, OR = 1.069 (95% CI, 1.024-1.116, P = 0.002). When ad-
justment was made for age, blood pressure and serum es-
tradiol concentration were added (Model 2), the observed 
association remained significant and its magnitude did 
not change.
diSCuSSion
Our results suggest a positive association between the 
number of (TA)n repeats in the promoter region of ESR1 
and the prevalence of lone AF in men. The significance of 
the observed relationship after adjustment for age, serum 
estradiol, and blood pressure indicates that the effect of 
(TA)n is independent of these putative confounders.
The basic role of estrogens in both sexes is modulation 
of immune responses, oxidative stress, inflammation, cel-
lular growth, proliferation and apoptosis, and affecting 
the central nervous, cardiovascular, and skeletal systems 
(13,19). Evidence suggests extragonadal production of 
sexual steroid hormones in the heart and blood vessels, as 
well as local effects of estrogens in the male heart, which 
are converted from testosterone by cytochrome P450 aro-
matase (20).
The proposed mechanisms by which sex steroids affect car-
diac electrophysiology include their effect on nuclear and 
extranuclear receptors in cardiomyocites (3,21,22), modu-
lating gene expression via many signaling pathways (23), 
but also non-genomic actions like influencing ion channel 
conductance and altering cell potentials (24).
tAbLe 2. Association between (tA)n repeats and lone atrial fibrillation in men
Models Variable odds ratio 95%  confidence interval P
Model 1 (univariable) number of (TA)n repeats 1.069 1.024-1.116 0.002
Model 2 (multivarable) number of (TA)n repeats 1.072 1.026-1.119 0.002
mean arterial pressure (mmHg) 1.006 0.958-1.056 0.809
age (years) 1.016 0.998-1.034 0.073
serum estradiol concentration (pmol/L) 0.997 0.981-1.013 0.692
FiGure 3. the association between the prevalence of lone 
atrial fibrillation and sums of (tA)n repeats of both alleles.
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ESR1 repeats are only one of many ESR1 polymorphisms 
(14) and their phenotypic expression is subtle (25). The mo-
lecular mechanism by which (TA)n repeat polymorphism 
may be associated with AF is unclear. The ESR1 gene has 
a very complex genomic organization containing multiple 
promoter regions with alternative splice sites, resulting in 
the expression of alternative first exons and different ER-α 
transcripts (26). It has been suggested that (TA)n dinucle-
otide repeat length may affect alternative promoter usage, 
resulting in unsuitable ER-α expression in certain tissues 
(27). In addition, a regulatory enhancer element that may 
act as a steroid response element has been identified ap-
proximately 200 base pairs downstream of the (TA)n repeat 
(28). Although the role of this enhancer is not yet clear, its 
proximity to the polymorphic repeat region makes it a po-
tential target for functional affects of (TA)n repeat number. 
It is also possible that the number of (TA)n repeats does 
not influence the heart directly, but via linkage disequilib-
rium with other coding regions.
Electrophysiological research on ESR1 polymorphisms has 
so far been mostly related to ventricular rather than to atri-
al arrhythmias. To our knowledge, this is the second report 
of the effect of the (TA)n repeat ESR1 polymorphism on 
atrial fibrillation, the first one being a small pilot-study that 
suggested a correlation between homozygosity for alleles 
with a larger number of (TA)n repeats and AF (15). Studies 
in other fields have shown that more (TA)n repeats lead 
to a less chemically active estrogen receptor, which is in 
agreement with our study (17,29).
Our study has several limitations. We were able to analyze 
only the (TA)n repeat polymorphism. It is possible that oth-
er polymorphisms of the same gene or polymorphisms of 
the gene encoding the estrogen receptor β could also be 
associated with lone AF. The study was limited to male par-
ticipants so the results may not be applicable to women.
Our results indicate that a greater number of (TA)n repeats 
in the promoter region of ESR1 is associated with an incre-
mental increase in the likelihood of lone AF in men. This 
result could give new insights into the role of steroid hor-
mones in the pathogenesis of AF. Large-scale studies con-
ducted in different populations are required to more com-
prehensively and reliably assess the relationship of (TA)n 
length with the quantity and quality of ER-α transcripts, 
and the occurrence of AF.
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